Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized Trials - PubMed
5 hours ago
- #gastric neoplasm
- #network meta-analysis
- #diabetes medications
- GLP-1 receptor agonists (GLP1RAs) are associated with a lower risk of gastric neoplasms compared to controls (RR = 0.51, 95% CI = 0.28-0.92).
- DPP-4 inhibitors (DPP4is) are associated with a higher risk of gastric neoplasms compared to controls (RR = 1.77, 95% CI = 1.09-2.85).
- These associations persist in subgroups, including participants with diabetes mellitus and trials with duration ≥52 weeks.
- No significant associations were found for SGLT2 inhibitors or in younger participants (<60 years) or shorter trials (<52 weeks).
- The findings suggest GLP1RAs may be preferable for gastric neoplasm risk in long-term therapy, while DPP4is require caution.
- The study emphasizes the need for improved neoplasms ascertainment in future trials rather than immediate prescribing changes.